NasdaqCM - Nasdaq Real Time Price USD

Cue Biopharma, Inc. (CUE)

0.7797
+0.0117
+(1.52%)
At close: May 9 at 4:00:02 PM EDT
0.7797
0.00
(0.00%)
After hours: May 9 at 4:00:13 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
9,287
9,287
5,490
1,245
14,941.3700
Operating Expense
50,880
50,880
57,482
54,747
58,653.4430
Operating Income
-41,593
-41,593
-51,992
-53,502
-43,712.0730
Net Non Operating Interest Income Expense
826
826
1,416
215
45.8980
Other Income Expense
93
93
-157
277
--
Pretax Income
-40,674
-40,674
-50,733
-53,010
-43,666.1750
Tax Provision
--
--
--
0
495
Net Income Common Stockholders
-40,674
-40,674
-50,733
-53,010
-44,161.1750
Diluted NI Available to Com Stockholders
-40,674
-40,674
-50,733
-53,010
-44,161.1750
Basic EPS
-0.91
-0.72
-1.11
-1.49
-1.41
Diluted EPS
-0.91
-0.72
-1.11
-1.49
-1.41
Basic Average Shares
49,518.9380
56,328.3480
45,754.7940
35,649.1340
31,285.4180
Diluted Average Shares
49,518.9380
56,328.3480
45,754.7940
35,649.1340
31,285.4180
Total Operating Income as Reported
-41,500
-41,500
-52,149
-53,225
-43,712.0730
Rent Expense Supplemental
--
--
716
899
--
Total Expenses
50,880
50,880
57,482
54,747
58,653.4430
Net Income from Continuing & Discontinued Operation
-40,674
-40,674
-50,733
-53,010
-44,161.1750
Normalized Income
-40,767
-40,767
-50,576
-53,287
-44,161.1750
Interest Income
1,622
1,622
2,661
928
45.8980
Interest Expense
796
796
1,245
713
0
Net Interest Income
826
826
1,416
215
45.8980
EBIT
-39,878
-39,878
-49,488
-52,297
-43,666.1750
EBITDA
-37,528
-37,528
-46,052
-50,491
-43,666.1750
Reconciled Depreciation
2,350
2,350
3,436
1,806
-1,777.9850
Net Income from Continuing Operation Net Minority Interest
-40,674
-40,674
-50,733
-53,010
-44,161.1750
Total Unusual Items Excluding Goodwill
93
93
-157
277
0
Total Unusual Items
93
93
-157
277
0
Normalized EBITDA
-37,621
-37,621
-45,895
-50,768
-43,666.1750
Tax Rate for Calcs
0
0
0
0
0.0003
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 1/2/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

RNTX Rein Therapeutics Inc.
1.7600
+1.15%
 
ACTU Actuate Therapeutics, Inc. Common stock
10.35
+4.55%
 
INAB IN8bio, Inc.
0.1574
-6.25%
 
RNXT RenovoRx, Inc.
1.0600
+1.92%
 
APS.TO Aptose Biosciences Inc.
2.2100
-0.45%
 
COYA Coya Therapeutics, Inc.
6.05
-2.58%
 
PHRRF PharmaTher Holdings Ltd.
0.1570
+3.09%
 
PBLA Panbela Therapeutics, Inc.
0.3110
+0.32%
 
SNSE Sensei Biotherapeutics, Inc.
0.3600
-4.41%
 
GANX Gain Therapeutics, Inc.
1.9400
-4.20%